scholarly journals A Novel Fully Human Agonistic Single Chain Fragment Variable Antibody Targeting Death Receptor 5 with Potent Antitumor Activity In Vitro and In Vivo

2017 ◽  
Vol 18 (10) ◽  
pp. 2064 ◽  
Author(s):  
Gaoxin Lei ◽  
Menglong Xu ◽  
Zhipan Xu ◽  
Lili Gu ◽  
Chenchen Lu ◽  
...  
Keyword(s):  
Antitumor Activity ◽  
Death Receptor ◽  
Death Receptor 5 ◽  
Single Chain ◽  
Chain Fragment ◽  
Single Chain Fragment Variable ◽  
Antibody Targeting ◽  
Single Chain Fragment

scholarly journals Single-Chain Fragment Variable Antibody Targeting Cholecystokinin-B Receptor For Pain Reduction

2021 ◽  
pp. 100067
Author(s):  
K.N. Westlund ◽  
M.A. Montera ◽  
A.E. Goins ◽  
S.R.A. Alles ◽  
M. Afaghpour-Becklund ◽  
...  
Keyword(s):  
Pain Reduction ◽  
Single Chain ◽  
Chain Fragment ◽  
Single Chain Fragment Variable ◽  
Antibody Targeting ◽  
Single Chain Fragment

scholarly journals Single-Chain Fragment Variables Targeting Leukocidin ED Can Alleviate the Inflammation of Staphylococcus aureus-Induced Mastitis in Mice

2021 ◽  
Vol 23 (1) ◽  
pp. 334
Author(s):  
Lei Zhang ◽  
Xin Ye ◽  
Yan Jia ◽  
Manling Cheng ◽  
Dangjin Wu ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Chemokine Receptors ◽  
Bovine Mastitis ◽  
Economic Losses ◽  
Single Chain ◽  
Necrosis Factor Alpha ◽  
Chain Fragment ◽  
Single Chain Fragment

Staphylococcus aureus is a vital bovine mastitis pathogen causing huge economic losses to the dairy industry worldwide. In our previous studies, leukotoxin ED (LukED) was detected in most S. aureus strains isolated from bovine mastitis. Here, four single-chain fragment variables (scFvs) (ZL8 and ZL42 targeting LukE, ZL22 and ZL23 targeting LukD) were obtained using purified LukE and LukD proteins as the antigens after five rounds of bio-panning. The complementarity-determining region 3 (CDR3) of the VH domain of these scFvs exhibited significant diversities. In vitro, the scFvs significantly decreased LukED-induced cell killing by inhibiting the binding of LukED to chemokine receptors (CCR5 and CXCR2) and reduced the death rates of bovine neutrophils and MAC-T cells caused by LukED and S. aureus (p < 0.05). In an S. aureus-induced mouse mastitis model, histopathology and MPO results revealed that scFvs ameliorated the histopathological damages and reduced the infiltration of inflammatory cells (p < 0.05). The ELISA and qPCR assays showed that scFvs reduced the transcription and expression levels of Tumor Necrosis Factor-alpha (TNF-α), interleukin-1β (IL-1β), IL-6, IL-8 and IL-18 (p < 0.05). The overall results demonstrated the protective anti-inflammatory effect of scFvs in vitro and in vivo, enlightening the potential role of scFvs in the prevention and treatment of S. aureus-induced mastitis.

scholarly journals In Vivo Human Single‐Chain Fragment Variable Phage Display‐Assisted Identification of Galectin‐3 as a New Biomarker of Atherosclerosis

2021 ◽  
Vol 10 (19) ◽  
Author(s):  
Audrey Hemadou ◽  
Alexandre Fontayne ◽  
Jeanny Laroche‐Traineau ◽  
Florence Ottones ◽  
Philippe Mondon ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Phage Display ◽  
Great Promise ◽  
Single Chain ◽  
Chain Fragment ◽  
Plaque Disruption ◽  
Single Chain Fragment Variable ◽  
Galectin 3 ◽  
Single Chain Fragment

Background Atherosclerosis is a complex pathology in which dysfunctional endothelium, activated leucocytes, macrophages, and lipid‐laden foam cells are implicated, and in which plaque disruption is driven by many putative actors. This study aimed to identify accurate targetable biomarkers using new in vivo approaches to propose tools for improved diagnosis and treatment. Methods and Results Human scFv (single‐chain fragment variable) selected by in vivo phage display in a rabbit model of atherosclerosis was reformatted as scFv fused to the scFv‐Fc (single‐chain fragment variable fused to the crystallizable fragment of immunoglobulin G format) antibodies. Their reactivity was tested using flow cytometry and immunoassays, and aorta sections from animal models and human carotid and coronary artery specimens. A pool of atherosclerotic proteins from human endarterectomies was co‐immunoprecipitated with the selected scFv‐Fc followed by mass spectrometry for target identification. Near‐infrared fluorescence imaging was performed in Apoe −/− mice after injection of an Alexa Fluor 647–labeled scFv‐Fc‐2c antibody produced in a baculovirus system with 2 additional cysteine residues (ie, 2c) for future coupling to nano‐objects for theranostic applications. One scFv‐Fc clone (P3) displayed the highest cross‐reactivity against atherosclerotic lesion sections (rabbit, mouse, and human) and was chosen for translational development. Mass spectrometry identified galectin‐3, a β‐galactoside‐binding lectin, as the leader target. ELISA and immunofluorescence assays with a commercial anti‐galectin‐3 antibody confirmed this specificity. P3 scFv‐Fc‐2c specifically targeted atherosclerotic plaques in the Apoe −/− mouse model. Conclusions These results provide evidence that the P3 antibody holds great promise for molecular imaging of atherosclerosis and other inflammatory pathologies involving macrophages. Recently, galectin‐3 was proposed as a high‐value biomarker for the assessment of coronary and carotid atherosclerosis.

Sign in / Sign up

Export Citation Format

Share Document